ATG-017 is a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 (ERK1/2) inhibitor with best-in-class potential. Antengene Corporation owns the global rights of ATG-017.
The RAS/MAPK pathway is an amplification cascade regulating many important cellular processes. ERK is a focal point on the RAS/MAPK pathway. ERK 1 and ERK 2 directly control the output of the pathway and negative feedback. An ERK inhibitor enables the targeting of both RAS and BRAF mutant disease.
ATG-017 has an open investigational new drug (IND) application for treatment of multiple solid tumors including non-small cell lung cancer, hepatocellular carcinoma, melanoma, renal cell carcinoma, etc.